Oral Semaglutide Cuts Heavy Drinking; VA Launches Alcoholism Trial
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
Substance Use Disorders
DiseaseRelated News
Neuroscience Studies Reveal Brain Mechanisms Behind Anxiety and Compulsive Behavior
Two neuroscience studies reveal brain mechanisms behind anxiety and compulsive behavior. One found restoring balance in an amygdala circuit reversed anxiety in mice, while another showed inflammation in the striatum makes behavior more deliberate.
GLP-1 Drugs Show Promise in Treating Addiction Across Multiple Substances
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
GLP-1 Drugs Show Protective Effects Against Addictions, Parkinson's, and Endometrial Cancer
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
GLP-1 Medications Reduce Risk of Substance Use Disorders and Overdose Deaths, Study Finds
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Psychedelic Therapies Advance in Depression Trials with Mixed Results
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
GLP-1 Therapies Show Antiinflammatory and Cardiovascular Benefits Beyond Metabolic Effects
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
GLP-1 Drugs Under Scrutiny for Pancreatitis Risk and Athletic Use
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07735481 |
Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention |
NOT_YET_RECRUITING | NA |
| NCT07707115 |
Interprofessional Simulation Program for Clinical Resilience and Empathy: Project INSPIRE |
RECRUITING | NA |
| NCT07705113 |
Effectiveness of Depression and Substance Use Module for Patients With Co-occurring Disorders |
ACTIVE_NOT_RECRUITING | NA |
| NCT07692984 |
The Effect of Comorbid Alcohol/Substance Use |
RECRUITING | |
| NCT07575373 |
Feasibility of an Interdisciplinary Intervention to Improve Care Transitions for Hospitalized Patients With Substance Use Disorders |
RECRUITING | NA |
| NCT07555145 |
Supporting Treatment Access and Recovery in Re-entry (STAR-R) |
NOT_YET_RECRUITING | NA |
| NCT07529327 |
Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups and Individualized Services |
RECRUITING | NA |
| NCT07519759 |
Recovery Inspired Support Engagement (RISE) Pilot |
NOT_YET_RECRUITING | NA |
| NCT07499583 |
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07417579 |
Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders |
COMPLETED |